Source: International Business Times
NEW YORK — Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical giant's flat revenue guidance for 2026 and ongoing pressures from declining COVID-19 product sales. Illustration shows Pfizer logo Pfizer stock (NYSE: PFE) rose to around $27.
Aller á la Source
Nouvelles connexes
